Rituximab as therapy for autoantibody mediated fibromyalgia (RAFT) - proof of concept
This research study, called RAFT, is investigating a medicine called rituximab to see if it can help people who suffer from fibromyalgia. Fibromyalgia is a long-term condition that causes widespread body pain and other symptoms. The main aim of the study is to find out if rituximab can significantly reduce pain levels after 16 weeks of treatment. Researchers will also look at how patients feel their symptoms have improved and if the medication affects certain cells in the body that are thought to be linked to pain. This is a Phase III trial, meaning it's a critical step in confirming if rituximab is a safe and effective treatment for fibromyalgia before it could potentially be made widely available.
At a glance
What is this study about?
This study, known by its short name RAFT, is exploring a new way to treat fibromyalgia. Fibromyalgia is a condition that causes ongoing, widespread pain throughout the body, as well as fatigue, sleep problems, and other symptoms. Currently, there isn't a cure, so treatments focus on managing the symptoms. This study is focusing on a medicine called rituximab, which works by targeting certain cells in the body.
The researchers believe that in some people with fibromyalgia, their own immune system might be involved in causing the pain. They are testing rituximab to see if it can help by calming down this part of the immune system. The main thing they want to find out is if people taking rituximab experience a significant reduction in their pain levels after about four months (16 weeks) of treatment. They will measure this using a standard pain scale.
Beyond just pain, the study will also look at other important things. They want to see if rituximab improves how patients feel about their overall fibromyalgia symptoms and their general well-being. They'll also be looking at specific changes in the body, such as how some cells (called satellite glia cells) that are thought to be involved in pain react to the treatment. This is a 'Therapeutic confirmatory' study, also known as a Phase III trial, which means it's a big step towards understanding if rituximab could become a new option for people with fibromyalgia.
Key takeaways
- The study investigates rituximab for fibromyalgia pain relief.
- It's a Phase III trial, a critical step in drug development.
- The main goal is to reduce pain over 16 weeks.
- It also checks overall symptom improvement and body changes.
- Participants will receive rituximab and other common medications.
Who may be eligible?
To be part of this study, you need to be at least 18 years old. There's no upper age limit, so people of all adult ages can be considered. Both men and women are welcome to take part in this research.
It's important to remember that just meeting these basic points doesn't guarantee you can join. There will be other health checks and criteria that the study doctors will need to review to make sure the study is safe and suitable for you. They'll also need to confirm that your fibromyalgia is typical of what they are looking to study.
The research team will carry out a full assessment to ensure the study is the right fit. This helps to protect your safety and ensure the study results are as accurate as possible.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of fibromyalgia?
- Are you able to attend clinic visits regularly?
- Are you willing to take the study medications as instructed?
What does participation involve?
If you decide to take part in this study, you would receive specific medications: Paracetamol ABECE, Medrol, Cetirizin ABECE, and Rituximab. These would be given to you as part of the study plan. The main focus is to see how your pain changes after 16 weeks of treatment with rituximab. You would have regular check-ups and assessments where your pain levels would be measured using a Visual Analogue Scale (VAS). You'd also complete questionnaires, such as the Fibromyalgia Impact Questionnaire (FIQ) and the Patient Global Impression of Change (PGIC), to describe how your fibromyalgia symptoms are affecting you and how you feel you've improved. There would also be tests to look at certain cells in your body to understand how the treatment is working. The study's main observation period for the rituximab treatment lasts 16 weeks, with checks before, during, and after this time.
Potential risks and benefits
Locations (1)
- —UnverifiedSweden
Common questions
What is fibromyalgia?
Fibromyalgia is a condition that causes long-lasting, widespread pain throughout the body, along with other symptoms like severe tiredness and sleep problems.
What is rituximab?
Rituximab is a medicine that works by affecting certain parts of the body's immune system. It's currently used for other conditions, and this study aims to see if it can help with fibromyalgia.
How long will the treatment part of the study last?
The main treatment period focusing on rituximab lasts for 16 weeks (about four months).
Will I have to take other medicines?
Yes, as part of the study, you would also receive Paracetamol ABECE, Medrol, and Cetirizin ABECE alongside rituximab. The research team will explain why.
What does Phase III mean?
Phase III means this is a key stage of research to check if a new treatment is effective and safe. It comes after earlier studies have shown promising results.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.